CTLA4 and cancer: These patients may have a defect in earlier steps in the cancer immunity cycle, and combinational immunotherapy including anti-OX40, anti-CTLA4, or anti-angiogenic with PD-1/L1 inhibition may be required to promote tumor immune cell infiltration and improve prognosis [40, 41].